Madhya Pradesh Online Journal

(Albany, US) On November 02, 2026, DelveInsight’s “EGFR-Induced Skin Disorders Market Insights, Epidemiology and Market Forecast – 2036” report provides comprehensive insights into the EGFR Inhibitor-Induced Skin Disorders market and pipeline landscape across the 7MM. It covers marketed and emerging drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type, and examines the market drivers and barriers shaping the space.

Discover the latest drugs and treatment options in the EGFR Inhibitors-Induced Skin Disorders Pipeline @ EGFR Inhibitors-Induced Skin Disorders market

Key Takeaways from the EGFR Inhibitors-Induced Skin Disorders Report

• In March 2026, Hoth Therapeutics reported pharmacokinetic, safety, and clinical activity data for HT-001 in cancer patients with EGFR therapy-associated skin toxicities, showing favorable tolerability, no serious adverse events, minimal systemic absorption, and reductions in symptom severity.

• In September 2025, Hoth submitted a clinical trial application to the EMA to expand its ongoing Phase II trial of HT-001.

• In August 2025, Azitra announced dosing of the first patient in its Phase I/II trial of ATR04-484 (ATR-04), a topical live biotherapeutic for EGFR inhibitor-associated rash, which holds FDA Fast Track designation.

• In June 2025, Lutris Pharma presented additional positive Phase II data for LUT-014 gel in acneiform rash associated with anti-EGFR therapies at the ESMO Gastrointestinal Cancers Congress 2025. LUT-014 holds Orphan Drug Designation for EGFR-induced acneiform rash.

• No therapies are approved specifically for EGFR inhibitor-induced skin disorders, and management relies on supportive care such as topical corticosteroids, emollients, antibiotics, and antihistamines.

• Dermatologic toxicity affects most patients on EGFR inhibitors, with acneiform rash reported in about 50 to 90% of treated patients. The US holds the largest patient share among the 7MM, with about 13,000 cases in NSCLC in 2025.

• DelveInsight’s report depicts an early-stage space where the pipeline is expanding toward targeted topical and microbiome-based dermatology-oncology therapies.

• Leading EGFR Inhibitors-Induced Skin Disorders companies include Lutris Pharma, Hoth Therapeutics, Azitra, and others.

• Promising therapies include LUT-014, HT-001, ATR-04, and others.

Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ EGFR Inhibitors-Induced Skin Disorders market research

EGFR Inhibitors-Induced Skin Disorders Overview

EGFR inhibitor-induced skin disorders are dermatologic toxicities caused by EGFR-targeted therapies used in non-small cell lung, colorectal, head and neck, pancreatic, and breast cancers. EGFR plays a critical role in skin homeostasis, keratinocyte proliferation, and hair follicle function, so inhibiting it produces acneiform rash, dry skin (xerosis), pruritus, eczema, paronychia, fissures, and hair abnormalities. These toxicities affect most treated patients and can impair quality of life, compromise adherence, and force dose changes. Diagnosis is clinical, based on history, timing relative to EGFR inhibitor start, and severity grading using CTCAE. Management is supportive and symptom-based: moisturizers, sunscreen, topical corticosteroids, topical or oral antibiotics (doxycycline, minocycline), antihistamines, and, in severe cases, systemic corticosteroids and dose reduction or interruption.

Common manifestations include:

• Acneiform (papulopustular) rash

• Dry skin and fissures

• Itching (pruritus)

• Paronychia and nail toxicities

• Eczema-like reactions and hair abnormalities

EGFR Inhibitors-Induced Skin Disorders Emerging Drugs Profile

LUT-014: Lutris Pharma LUT-014 is a proprietary, first-in-class topical B-Raf inhibitor small molecule being developed for acneiform lesions induced by EGFR inhibitors. It has Orphan Drug Designation for EGFR-induced acneiform rash and has also completed a Phase I study in radiation-induced dermatitis in breast cancer patients. Currently, the drug is in Phase II.

HT-001: Hoth Therapeutics HT-001 is a topical formulation for mild to moderate rash and skin disorders associated with tyrosine kinase inhibitor/EGFR inhibitor therapy, designed to reduce inflammation and restore the skin barrier. The Phase IIa CLEER trial is underway, with interim results highlighting preservation of cancer treatment while resolving skin side effects. Currently, the drug is in Phase II.

ATR-04 (ATR04-484): Azitra ATR-04 is a topical live biotherapeutic product based on an engineered Staphylococcus epidermidis strain, modified to be safer by deleting an antibiotic resistance gene and adding auxotrophy to control its growth. It aims to restore skin microbial balance and barrier function and modulate inflammation in EGFR inhibitor-associated rash. It holds FDA Fast Track designation. Currently, the drug is in Phase I/II.

Explore groundbreaking therapies and clinical trials in the EGFR Inhibitors-Induced Skin Disorders Pipeline @ EGFR Inhibitors-Induced Skin Disorders market insight

EGFR Inhibitors-Induced Skin Disorders Market Drivers

• Expanding EGFR inhibitor use: Wider adoption across NSCLC, colorectal, pancreatic, head and neck, and breast cancers is increasing the population exposed to skin toxicities.

• High toxicity burden: Dermatologic adverse events occur in most treated patients and affect adherence, dose intensity, and quality of life.

• No approved disease-specific therapy: The absence of targeted options creates a clear opening for new entrants.

• Targeted, differentiated pipeline: Topical kinase inhibitors, skin barrier restoration agents, and microbiome-based therapies address underlying mechanisms rather than symptoms alone.

• Regulatory support: Orphan Drug Designation and Fast Track designations support development.

• Oncology-dermatology crossover: Growing focus on keeping patients on anticancer therapy is increasing demand for supportive-care innovation.

• Strong US market conditions: High EGFR therapy use, strong oncology infrastructure, and rapid adoption of supportive care products favor commercial uptake.

Learn about new drugs, pipeline developments, and key players with DelveInsight’s expert analysis @ EGFR Inhibitors-Induced Skin Disorders market trends

EGFR Inhibitors-Induced Skin Disorders Market Barriers

• Entrenched low-cost supportive care: Generic corticosteroids, emollients, and tetracycline antibiotics are widely used and inexpensive.

• Early-stage pipeline: Candidates are in Phase I/II or Phase II, with clinical and regulatory risk and limited head-to-head evidence.

• Preserving anticancer efficacy: New topicals must show they do not interfere with EGFR inhibitor activity.

• Lack of biomarkers and standard algorithms: The absence of predictive biomarkers and standardized treatment makes patient selection and trial design harder.

• Fragmented patient pool: Cases are spread across several cancer types and EGFR therapies, complicating recruitment and commercial targeting.

• Reactive treatment patterns: Management is largely reactive, and prophylactic use of new products may need new guidelines.

• Reimbursement uncertainty: Payers may question paying for premium supportive-care products against inexpensive alternatives.

Scope of the EGFR Inhibitors-Induced Skin Disorders Report

• Coverage: 7MM (US, EU4, UK, Japan)

• Companies: As listed above

• Therapies: LUT-014, HT-001, ATR-04, and others

• Assessment by Product Type: Mono, Combination, Mono/Combination

• Assessment by Clinical Stage: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Download DelveInsight’s in-depth EGFR Inhibitors-Induced Skin Disorders report

Table of Contents

1. Introduction

2. Executive Summary

3. EGFR Inhibitors-Induced Skin Disorders: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. DelveInsight’s Analytical Perspective

7. Late Stage Products (Phase III): None currently

8. Mid Stage Products (Phase II): LUT-014 (Lutris Pharma), HT-001 (Hoth Therapeutics)

9. Early Stage Products (Phase I): ATR-04 (Azitra), Phase I/II

10. Preclinical and Discovery Stage Products

11. Inactive Products

12. Key Companies

13. Key Products

14. Unmet Needs

15. Market Drivers and Barriers

16. Future Perspectives and Conclusion

17. Analyst Views

18. Appendix

19. About Us

About DelveInsight DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Mehul Malhotra
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting